FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212612169> ?p ?o ?g. }

• W3212612169 endingPage "1165" @default.
• W3212612169 startingPage "1165" @default.
• W3212612169 abstract "Abstract Introduction: Notwithstanding recent progress, acute myeloid leukemia (AML) remains an incurable disease, particularly in patients (pts) with relapsing/refractory disorder or ineligible for intensive induction therapy (unfit pts). Redirected T-cell mediated killing via CD3-engaging bispecific molecules may offer an alternate therapeutic opportunity for aggressive disease or unfit pts. Flotetuzumab, a continuous infusion CD123 x CD3 DART molecule, has shown preliminary single-agent activity in pts refractory to induction therapy (Uy et al., Blood. 2021, 137:751). CD123, the IL-3 receptor alpha chain, is expressed by both leukemic blasts and leukemic stem cells and is a suitable therapeutic target in AML (Testa et al., Cancers (Basel). 2019, 11:1358). MGD024 is an Fc-bearing CD123 x CD3 DART molecule designed for prolonged circulating half-life and intermittent delivery. MGD024 was also designed with a CD3-binding arm with reduced affinity to diminish the propensity for cytokine release compared to flotetuzumab. The potentially improved tolerability and dosing convenience of MGD024 may provide a framework for introducing T-cell immunotherapy in early-stage AML or unfit pts. To explore whether MGD024 could complement AML standard of care (SOC), we investigated combination therapy in mouse models. Materials and Methods: The DART molecules, flotetuzumab and MGD024, shared identical CD123 (humanized 7G3) and CD3 (humanized XR32) Fv arms, save for a mutation in the anti-CD3 arm of MGD024 that decreases its affinity for the CD3-epsilon chain. While flotetuzumab has no Fc domain, MGD024 includes an ala-ala-mutated human IgG1 Fc that extends its circulating half-life via the neonatal Fc receptor-mediated salvage pathway together with impairing binding to Fc-gamma receptors and complement. An IgG1-ala-ala Fc-bearing version of flotetuzumab (RES234M1.1) was also engineered to allow delivery at identical time intervals as MGD024 and avoid continuous infusion in experimental animals. MHC class I-null, NOD/SCID/IL2R-gamma-null mice were reconstituted with human PBMC (8x10 6 cells/mouse, retro orbital). Two human AML cell lines expressing low or high levels of CD123 (KG1a &lt; MOLM-13) were implanted SC at 2.5 x 10 6 (KG1a) or 5 x 10 6 (MOLM-13) cells/mouse. Treatments (IV, IP or PO by gavage, as indicated) were initiated when tumor volumes reached ~150 mm 3, with volumes recorded weekly or twice weekly thereafter. Results and Conclusions: Consistent with its decreased affinity for CD3, MGD024 demonstrated reduced in vitro potency in killing CD123-positive target cells compared to flotetuzumab or RES234M1.1, but proportionally greater reduction in cytokine release. MGD024, however, achieved maximal cytolytic activity as flotetuzumab or RES234M1.1, albeit at increased concentrations. Similarly, MGD024 showed reduced potency in vivo against CD123-positive tumors compared to RES234M1.1; nevertheless, tumor growth reduction of the same magnitude as that observed with RES234M1.1 was attained at higher doses of MGD024 (0.5-1 mg/kg IV 2QW MGD024 vs. 0.05-0.1 mg/kg IV 2QW RES234M1.1, depending on the model). Reduced cytokine release was also observed with MGD024 compared to RES234M1.1 in vivo. To explore MGD024 suitability for combination therapy, sub-active doses of cytarabine (CYT, 10 mg/kg IV 2QW or 7.5-10 mg/kg IP QD), venetoclax (VEN, range 10-80 mg/kg PO QD), or azacitidine (AZA, 2 mg/kg PO QD) were co-administered with suboptimal regimens of MGD024 (range 0.005-0.1 mg/kg IV 2QW, depending on the model). Complete or near complete tumor elimination was observed with the combination of suboptimal MGD024 and CYT or VEN. In contrast, AZA, at the dose tested, did not contribute to the antitumor effect of MGD024. CYT, VEN or AZA did not inhibit a fully active dose of MGD024, confirming no detrimental impact of the SOC agents at the doses employed on the effector cell population engaged by the DART molecule. All treatments were well tolerated, as indicated by body weigh profiles across treatment groups. These data support clinical exploration of the combination of MGD024 with SOC in patients with AML. An investigational new drug (IND) application of MGD024 in pts with selected relapsed or refractory hematologic malignancies is planned. Disclosures Alderson: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Huang: MacroGenics: Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Ended employment in the past 24 months. Zhang: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Li: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Kaufman: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Diedrich: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Moore: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Bonvini: MacroGenics: Current Employment, Current equity holder in publicly-traded company, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company." @default.
• W3212612169 created "2021-11-22" @default.
• W3212612169 creator A5003749078 @default.
• W3212612169 creator A5009027578 @default.
• W3212612169 creator A5023294934 @default.
• W3212612169 creator A5053693367 @default.
• W3212612169 creator A5063880073 @default.
• W3212612169 creator A5066737474 @default.
• W3212612169 creator A5080629319 @default.
• W3212612169 creator A5090580398 @default.
• W3212612169 date "2021-11-05" @default.
• W3212612169 modified "2023-10-16" @default.
• W3212612169 title "Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific Dart® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia" @default.
• W3212612169 doi "https://doi.org/10.1182/blood-2021-153192" @default.
• W3212612169 hasPublicationYear "2021" @default.
• W3212612169 type Work @default.
• W3212612169 sameAs 3212612169 @default.
• W3212612169 citedByCount "5" @default.
• W3212612169 countsByYear W32126121692022 @default.
• W3212612169 countsByYear W32126121692023 @default.
• W3212612169 crossrefType "journal-article" @default.
• W3212612169 hasAuthorship W3212612169A5003749078 @default.
• W3212612169 hasAuthorship W3212612169A5009027578 @default.
• W3212612169 hasAuthorship W3212612169A5023294934 @default.
• W3212612169 hasAuthorship W3212612169A5053693367 @default.
• W3212612169 hasAuthorship W3212612169A5063880073 @default.
• W3212612169 hasAuthorship W3212612169A5066737474 @default.
• W3212612169 hasAuthorship W3212612169A5080629319 @default.
• W3212612169 hasAuthorship W3212612169A5090580398 @default.
• W3212612169 hasBestOaLocation W32126121691 @default.
• W3212612169 hasConcept C104317684 @default.
• W3212612169 hasConcept C114684123 @default.
• W3212612169 hasConcept C147483822 @default.
• W3212612169 hasConcept C150194340 @default.
• W3212612169 hasConcept C167672396 @default.
• W3212612169 hasConcept C185592680 @default.
• W3212612169 hasConcept C190727270 @default.
• W3212612169 hasConcept C203014093 @default.
• W3212612169 hasConcept C2776239401 @default.
• W3212612169 hasConcept C2777701055 @default.
• W3212612169 hasConcept C2777938653 @default.
• W3212612169 hasConcept C2778041864 @default.
• W3212612169 hasConcept C2778461978 @default.
• W3212612169 hasConcept C2778729363 @default.
• W3212612169 hasConcept C2779675984 @default.
• W3212612169 hasConcept C502942594 @default.
• W3212612169 hasConcept C55493867 @default.
• W3212612169 hasConcept C71924100 @default.
• W3212612169 hasConcept C83396363 @default.
• W3212612169 hasConcept C8891405 @default.
• W3212612169 hasConcept C98274493 @default.
• W3212612169 hasConceptScore W3212612169C104317684 @default.
• W3212612169 hasConceptScore W3212612169C114684123 @default.
• W3212612169 hasConceptScore W3212612169C147483822 @default.
• W3212612169 hasConceptScore W3212612169C150194340 @default.
• W3212612169 hasConceptScore W3212612169C167672396 @default.
• W3212612169 hasConceptScore W3212612169C185592680 @default.
• W3212612169 hasConceptScore W3212612169C190727270 @default.
• W3212612169 hasConceptScore W3212612169C203014093 @default.
• W3212612169 hasConceptScore W3212612169C2776239401 @default.
• W3212612169 hasConceptScore W3212612169C2777701055 @default.
• W3212612169 hasConceptScore W3212612169C2777938653 @default.
• W3212612169 hasConceptScore W3212612169C2778041864 @default.
• W3212612169 hasConceptScore W3212612169C2778461978 @default.
• W3212612169 hasConceptScore W3212612169C2778729363 @default.
• W3212612169 hasConceptScore W3212612169C2779675984 @default.
• W3212612169 hasConceptScore W3212612169C502942594 @default.
• W3212612169 hasConceptScore W3212612169C55493867 @default.
• W3212612169 hasConceptScore W3212612169C71924100 @default.
• W3212612169 hasConceptScore W3212612169C83396363 @default.
• W3212612169 hasConceptScore W3212612169C8891405 @default.
• W3212612169 hasConceptScore W3212612169C98274493 @default.
• W3212612169 hasIssue "Supplement 1" @default.
• W3212612169 hasLocation W32126121691 @default.
• W3212612169 hasOpenAccess W3212612169 @default.
• W3212612169 hasPrimaryLocation W32126121691 @default.
• W3212612169 hasRelatedWork W2899412336 @default.
• W3212612169 hasRelatedWork W3048827006 @default.
• W3212612169 hasRelatedWork W3131716652 @default.
• W3212612169 hasRelatedWork W4244285644 @default.
• W3212612169 hasRelatedWork W4255364295 @default.
• W3212612169 hasRelatedWork W4283514695 @default.
• W3212612169 hasRelatedWork W4293253462 @default.
• W3212612169 hasRelatedWork W4310159665 @default.
• W3212612169 hasRelatedWork W4362542584 @default.
• W3212612169 hasRelatedWork W4362592484 @default.
• W3212612169 hasVolume "138" @default.
• W3212612169 isParatext "false" @default.
• W3212612169 isRetracted "false" @default.
• W3212612169 magId "3212612169" @default.
• W3212612169 workType "article" @default.